Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616-Reference-Cited by-同舟云学术

Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616

Published:2023-04 Issue:16 Volume:81 Page:1553-1564
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Ballantyne Christie M.,Banka Puja,Mendez Gustavo,Garcia Raymundo,Rosenstock Julio,Rodgers Anthony,Mendizabal Geraldine,Mitchel Yale,Catapano Alberico L.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference30 articles.

1. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel;Ference;Eur Heart J,2017

2. Evaluation of dyslipidaemia and the impact of hypolipidemic therapy on prognosis in high and very high risk patients through the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) Registry;Dyrbuś;Pharmacol Res,2018

3. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins;Fox;Clin Res Cardiol,2018

4. Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients;Gitt;Atherosclerosis,2016

5. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study;Ray;Eur J Prevent Cardiol,2021

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease;JAMA Cardiology;2024-09-01

2. The role of proprotein convertase subtilisin/kexin 9 (PCSK9) in macrophage activation: a focus on its LDL receptor-independent mechanisms;Frontiers in Cardiovascular Medicine;2024-08-01

3. LabrafacTM MC60 is an efficacious intestinal permeation enhancer for macromolecules: Comparisons with Labrasol® ALF in ex vivo and in vivo rat studies;International Journal of Pharmaceutics;2024-08

4. Lipid nanoparticle (LNP) mediated mRNA delivery in cardiovascular diseases: Advances in genome editing and CAR T cell therapy;Journal of Controlled Release;2024-08

5. Medications for Lipid Control: Statins vs Newer Drugs;Canadian Journal of Cardiology;2024-08